跳至主要内容
临床试验/NCT01860833
NCT01860833已完成4 期

EFFECTS OF NSAIDs ON CLINICAL OUTCOMES, SYNOVIAL FLUID CYTOKINE CONCENTRATION AND SIGNAL TRANSDUCTION PATHWAYS IN KNEE OSTEOARTHRITIS

University of Catanzaro1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
Western Ontario and McMaster universities (WOMAC) osteoarthritis index score

研究概览

简要总结

Central mechanisms may play a role in pain perception during osteoarthritis (OA).Local inflammation (which involves production of pro-inflammatory cytokines such as interleukin (IL) 4 TNF-alpha, IL-6 and IL-8) is considered to be a major source of pain.

Certain therapies that specifically interfere with the expression or actions of pro-inflammatory cytokines have been explored. NSAIDs have analgesic, antipyretic and anti-inflammatory properties and are extensively prescribed for several musculoskeletal disorders. Indeed, the Osteoarthritis Research Society International (OARSI) recently recommended the use of NSAIDs for management of knee and hip OA in symptomatic patients. These drugs have been shown to influence cytokine metabolism in the synovial fluid of OA patients with satisfactory relief of painful osteoarthritic joints.

The aim of the current study was to explore whether NSAID treatment inhibits TNF-alpha, IL-6, IL-8, and VEGF secretion in the synovial fluid of osteoarthritic joints. In particular, diclofenac, ibuprofen and celecoxib were studied. Under the hypothesis that relationships between proinflammatory cytokines and the clinical status of OA patients are possible, we also evaluated the association between the concentration of these molecules in the osteoarthritic knee synovial fluid and the pain and functional status of patients with OA. The effects of NSAIDS on signal transduction pathways in the synovial membrane were also investigated.

详细描述

not desired

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients eligible for the study were:
  • older than 50 years and
  • had primary knee OA diagnosed according to the clinical and radiological criteria of the American Rheumatism Association.
  • Further inclusion criteria were:
  • clinical signs of joint inflammation (warmth, swelling or effusion) and
  • a disease severity grade 2 or 3 according to the Kellgren-Lawrence classification

排除标准

  • allergy to NSAIDs,
  • progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease),
  • history of gastrointestinal ulcer or bleeding,
  • a hemoglobin concentration lower than 11.5 g/dL,
  • renal diseases (serum creatinine concentration more than 1.2 times the upper limit of the normal range according to the central laboratory definition reference values), or
  • liver dysfunction (serum alanine or aspartate transaminase concentrations more than 1.5 times the upper limit of normal range according to the central laboratory definition reference values).

研究组 & 干预措施

diclofenac 75 mg/day

Active Comparator

diclofenac 75 mg once day slow release

干预措施: Diclofenac (Drug)

diclofenac 150 mg/day

Active Comparator

diclofenac 75 mg bid

干预措施: Diclofenac (Drug)

ibuprofen 1200 mg/day

Active Comparator

ibuprofen 600 mg bid

干预措施: Ibuprofen (Drug)

ibuprofen 1800 mg/day

Active Comparator

ibuprofen 600 mg tid

干预措施: Ibuprofen (Drug)

celecoxib 200 mg/day

Active Comparator

celecoxib 200 mg once day

干预措施: Celecoxib (Drug)

celecoxib 400 mg/day

Active Comparator

celecoxib 200 mg bid

干预措施: Celecoxib (Drug)

结局指标

主要结局

Western Ontario and McMaster universities (WOMAC) osteoarthritis index score

时间窗: 0-14 days

Womac was used to 77 measure the disease-specific health status of patients before and after the pharmacological treatment.

次要结局

  • Naranjo probability scale(14 days)

研究者

发起方
University of Catanzaro
申办方类型
Other
责任方
Principal Investigator
主要研究者

Luca Gallelli

MD

University of Catanzaro

研究点 (1)

Loading locations...

相似试验